[go: up one dir, main page]

DK3268374T3 - Kv1.3-inhibitorer og deres medicinske anvendelse - Google Patents

Kv1.3-inhibitorer og deres medicinske anvendelse Download PDF

Info

Publication number
DK3268374T3
DK3268374T3 DK16709802.9T DK16709802T DK3268374T3 DK 3268374 T3 DK3268374 T3 DK 3268374T3 DK 16709802 T DK16709802 T DK 16709802T DK 3268374 T3 DK3268374 T3 DK 3268374T3
Authority
DK
Denmark
Prior art keywords
inhibitors
medical use
medical
Prior art date
Application number
DK16709802.9T
Other languages
English (en)
Inventor
Jürgen Kraus
Stefan Tasler
Ilga Krimmelbein
Mirko Zaja
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Application granted granted Critical
Publication of DK3268374T3 publication Critical patent/DK3268374T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
DK16709802.9T 2015-03-13 2016-03-14 Kv1.3-inhibitorer og deres medicinske anvendelse DK3268374T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15159080 2015-03-13
PCT/EP2016/055451 WO2016146583A1 (en) 2015-03-13 2016-03-14 Kv1.3 inhibitors and their medical application

Publications (1)

Publication Number Publication Date
DK3268374T3 true DK3268374T3 (da) 2020-01-02

Family

ID=52736854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16709802.9T DK3268374T3 (da) 2015-03-13 2016-03-14 Kv1.3-inhibitorer og deres medicinske anvendelse

Country Status (28)

Country Link
US (4) US10822345B2 (da)
EP (1) EP3268374B1 (da)
JP (1) JP6506409B2 (da)
KR (1) KR20170137056A (da)
CN (1) CN107548397B (da)
AU (1) AU2016232338B2 (da)
BR (1) BR112017019439A2 (da)
CA (1) CA2979503A1 (da)
CY (1) CY1122470T1 (da)
DK (1) DK3268374T3 (da)
EA (1) EA037194B1 (da)
ES (1) ES2762938T3 (da)
HK (1) HK1243997B (da)
HR (1) HRP20192258T1 (da)
IL (1) IL254391B (da)
LT (1) LT3268374T (da)
MX (1) MX373022B (da)
PH (1) PH12017501652A1 (da)
PL (1) PL3268374T3 (da)
PT (1) PT3268374T (da)
RS (1) RS59758B1 (da)
SG (1) SG11201707284PA (da)
SI (1) SI3268374T1 (da)
SM (1) SMT201900704T1 (da)
TW (1) TWI701249B (da)
UA (1) UA121493C2 (da)
WO (1) WO2016146583A1 (da)
ZA (1) ZA201705561B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
WO2019057821A1 (en) 2017-09-20 2019-03-28 Lead Discovery Center Gmbh COUMARIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND USES THEREOF IN THE TREATMENT OF CANCER
US10703735B2 (en) 2018-07-25 2020-07-07 Lead Discovery Center Gmbh 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
WO2020048548A1 (zh) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物
KR20210141587A (ko) 2019-03-20 2021-11-23 리드 디스커버리 센터 게엠베하 퀴놀린 유도체, 이들의 제조 공정 및 암 치료를 위한 이의 사용
EP4153598A1 (en) 2020-05-20 2023-03-29 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
CN115960112B (zh) * 2023-02-03 2024-02-20 北京大学深圳医院（北京大学深圳临床医学院） 一种花椒毒醇衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5729765A (en) 1980-10-08 1982-02-17 Yuuichi Yanagi Melting of snow on roof
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
AUPS127202A0 (en) 2002-03-20 2002-04-18 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic ion channel blocking agents and methods of use thereof
US7772408B1 (en) 2002-08-29 2010-08-10 The Regents Of The University Of California Substituted 5-alkoxypsoralens as inhibitors of potassium channel activity in lymphocytes and other cells
JP2006515274A (ja) 2002-10-08 2006-05-25 マサチューセッツ・インスティテュート・オブ・テクノロジー コレステロール輸送の調節のための化合物
ITPD20020325A1 (it) 2002-12-18 2004-06-19 Consorzio Interuniversitario Nazionale La Chimic Sintesi di aniline funzionalizzate mono-n-sostituite.
CN100486245C (zh) 2003-07-31 2009-05-06 中兴通讯股份有限公司 一种支持多媒体消息版权保护的多媒体消息业务实现方法
US7557138B2 (en) 2004-10-04 2009-07-07 The Regents Of The University Of California 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
WO2006096911A1 (en) 2005-03-15 2006-09-21 Harvey Andrew J Novel potassium channel blockers and uses thereof
JP2009504712A (ja) 2005-08-17 2009-02-05 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カリウムチャンネル阻害化合物の使用方法
WO2007139771A1 (en) 2006-05-22 2007-12-06 The Johns Hopkins University Kv channels in neurodegeneration and neuroprotection
NZ575686A (en) 2006-10-04 2012-02-24 Bionomics Ltd Novel chromenone potassium channel blockers and uses thereof
NZ575685A (en) 2006-10-04 2012-04-27 Bionomics Ltd Novel benzofuran potassium channel blockers and uses thereof
CN101307056B (zh) * 2007-05-16 2011-04-27 中国科学院上海药物研究所 线型呋喃香豆素衍生物、其制备方法和用途、以及包含该衍生物的药物组合物
CN101888989A (zh) 2007-10-04 2010-11-17 生态学有限公司 新型芳基钾通道阻断剂及其应用
US9114102B2 (en) 2007-11-07 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting ABCG2 and related treatments
JP2011522843A (ja) 2008-06-13 2011-08-04 バイオノミクス リミテッド 新規なカリウムチャンネルブロッカー及びその使用
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
TW201026708A (en) 2008-12-12 2010-07-16 Solvay Pharm Bv Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
CA2774327C (en) 2009-09-15 2019-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
CN102091067B (zh) * 2009-12-09 2013-04-10 中国科学院上海药物研究所 呋喃香豆素类化合物在制备药物中的新用途
WO2011073273A1 (en) 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073269A1 (en) 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073277A1 (en) 2009-12-16 2011-06-23 Evotec Ag PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS Kv1.3 MODULATORS
JP6166858B2 (ja) 2011-03-02 2017-07-19 バイオインセプト、エルエルシー 細胞内損傷の治療のための組成物および方法
US20140171455A1 (en) * 2011-06-09 2014-06-19 The Regents Of The University Of California Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition
JP2014531469A (ja) 2011-10-03 2014-11-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カ Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療
US11453899B2 (en) * 2016-03-31 2022-09-27 Toray Industries, Inc. Method of producing protein

Also Published As

Publication number Publication date
BR112017019439A2 (pt) 2018-05-15
UA121493C2 (uk) 2020-06-10
RS59758B1 (sr) 2020-02-28
TWI701249B (zh) 2020-08-11
US20200339592A1 (en) 2020-10-29
CY1122470T1 (el) 2021-01-27
AU2016232338B2 (en) 2020-09-03
EA201791816A1 (ru) 2018-04-30
EP3268374B1 (en) 2019-09-25
JP2018507892A (ja) 2018-03-22
ZA201705561B (en) 2020-01-29
SG11201707284PA (en) 2017-10-30
KR20170137056A (ko) 2017-12-12
PH12017501652B1 (en) 2018-03-12
HK1243997B (en) 2020-06-26
US10822345B2 (en) 2020-11-03
MX2017011650A (es) 2018-02-09
LT3268374T (lt) 2020-03-10
CN107548397A (zh) 2018-01-05
SI3268374T1 (sl) 2020-03-31
WO2016146583A1 (en) 2016-09-22
IL254391A0 (en) 2017-11-30
CA2979503A1 (en) 2016-09-22
PH12017501652A1 (en) 2018-03-12
TW201639843A (zh) 2016-11-16
AU2016232338A1 (en) 2017-10-05
HRP20192258T1 (hr) 2020-03-20
PL3268374T3 (pl) 2020-05-18
US20180051034A1 (en) 2018-02-22
ES2762938T3 (es) 2020-05-26
IL254391B (en) 2021-02-28
US20200377514A1 (en) 2020-12-03
PT3268374T (pt) 2019-12-23
EA037194B1 (ru) 2021-02-18
US20190185483A1 (en) 2019-06-20
EP3268374A1 (en) 2018-01-17
SMT201900704T1 (it) 2020-01-14
US10723743B2 (en) 2020-07-28
JP6506409B2 (ja) 2019-04-24
MX373022B (es) 2020-05-26
CN107548397B (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3337549T3 (da) Kateteranordninger med ventiler og tilhørende fremgangsmåder.
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3256598T3 (da) Svampestammer og anvendelsesfremgangsmåder
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf